Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.64 USD
Change Today +0.13 / 0.51%
Volume 84.4K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

paratek pharmaceuticals inc (PRTK) Snapshot

Open
$25.62
Previous Close
$25.51
Day High
$26.16
Day Low
$25.41
52 Week High
12/31/14 - $39.80
52 Week Low
10/24/14 - $11.30
Market Cap
450.3M
Average Volume 10 Days
67.2K
EPS TTM
$-8.50
Shares Outstanding
17.6M
EX-Date
10/31/14
P/E TM
--
Dividend
--
Dividend Yield
31.24%
Current Stock Chart for PARATEK PHARMACEUTICALS INC (PRTK)

paratek pharmaceuticals inc (PRTK) Related Bloomberg News

View More Bloomberg News

paratek pharmaceuticals inc (PRTK) Related Businessweek News

No Related Businessweek News Found

paratek pharmaceuticals inc (PRTK) Details

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

18 Employees
Last Reported Date: 05/15/15

paratek pharmaceuticals inc (PRTK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $10.4K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

paratek pharmaceuticals inc (PRTK) Key Developments

Paratek Pharmaceuticals, Inc. Appoints Timothy Franson to its Board of Directors

Paratek Pharmaceuticals, Inc. announced the appointment of Timothy Franson, M.D. as a new, independent director to its board of directors. This appointment, effective as of July 21, brings Paratek's total number of directors to seven, five of whom are independent. He currently serves as Chief Medical Officer for YourEncore. Dr. Franson has extensive clinical and regulatory experience in all pre- and post-approval phases of pharmaceutical development (small and large molecule) relating to interactions with the Food and Drug Administration for policy and product issues, as well as interactions with global regulators.

Paratek Pharmaceuticals, Inc. Opens New Corporate Headquarters in Boston

Paratek Pharmaceuticals, Inc. opened its new corporate headquarters in Boston at 75 Park Plaza. The address of the new headquarters is 75 Park Plaza, 4th floor, Boston, MA 02116. Paratek was previously located at 75 Kneeland Street in Boston. In June Paratek opened a second office location in the Philadelphia area.

Paratek Pharmaceuticals, Inc. Appoints William Haskel as Senior Vice President, General Counsel and Corporate Secretary

Paratek Pharmaceuticals, Inc. announced that William Haskel joined the company as Senior Vice President, General Counsel and Corporate Secretary. He will be based out of the company's Boston office. As General Counsel, Mr. Haskel is the firm's chief legal officer, providing legal advice to Paratek's Board of Directors and senior management. Mr. Haskel brings more than 20 years of experience in leading legal corporate development for life sciences companies. Most recently, Mr. Haskel served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Cambrex Corporation, where he was responsible for the global law function as well as overseeing Global Regulatory and Quality Affairs and Environment, Health and Safety. He was principal advisor for Board and Governance, M&A, Securities and Corporate matters, and he created the formal global compliance program.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTK:US $25.64 USD +0.13

PRTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTK.
View Industry Companies
 

Industry Analysis

PRTK

Industry Average

Valuation PRTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 85.7x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 82.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARATEK PHARMACEUTICALS INC, please visit www.paratekpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.